Four-Plaintiff Chicago Trial Opens Against Abbott Over Preterm Infant Formula

Why It Matters

The litigation threatens massive financial exposure for Abbott and could drive sweeping changes in infant‑formula safety standards, reshaping the market and regulatory oversight.

Key Takeaways

• Fourth U.S. trial alleges Abbott formula causes NEC
• Prior juries awarded $495M and $60M against manufacturers
• Missouri judge overturned verdict citing widespread misconduct
• MDL bellwether trial scheduled July 6 versus Mead Johnson
• Liability risk may reshape infant formula market dynamics

Pulse Analysis

The Chicago trial marks the latest escalation in a series of lawsuits linking preterm infant formula to necrotizing enterocolitis, a severe gastrointestinal disease with high mortality rates. While Abbott maintains its products meet FDA standards, plaintiffs argue that the cow‑milk base, combined with hospital feeding protocols, creates a toxic environment for vulnerable newborns. This legal focus reflects growing scrutiny of supply‑chain transparency and clinical testing rigor in the infant nutrition sector, prompting hospitals to re‑evaluate feeding practices and consider alternative formulations.

Recent verdicts have set a precedent for punitive damages in the infant‑formula arena. In 2024, juries in Missouri and Illinois awarded $495 million and $60 million, respectively, against Abbott and Mead Johnson, underscoring the willingness of courts to hold manufacturers accountable for alleged product harms. However, a Missouri judge later vacated a verdict, citing extensive misconduct, which highlights the complex evidentiary challenges in proving causation for NEC. The ongoing multidistrict litigation (MDL) consolidates dozens of related cases, with bellwether trials slated for mid‑year, offering a litmus test for how courts may balance scientific uncertainty against consumer protection.

For the industry, the stakes extend beyond courtroom payouts. Potential liabilities could trigger stricter FDA oversight, compel reformulation of products, and accelerate investment in human‑milk‑based alternatives. Investor confidence may waver as litigation costs rise, prompting companies to bolster risk‑management frameworks and enhance transparency with healthcare providers. Ultimately, the outcomes of these trials will shape the competitive landscape, influencing pricing, product development, and the trust parents place in infant nutrition brands.